Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | HAVCR2 | Q8TDQ0 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17175010 | 0.79 | TNKS (0.31) | TNKSPARP1TNKS2ALDH1A1 | |
| SCHEMBL10309385 | 0.70 | PDE10A (0.45) | HAVCR2HSD17B10PDE10A | |
| SCHEMBL22087003 | 0.69 | KDM4E (0.43) | HSD17B10POLBKDM4EALDH1A1LMNA | |
| SCHEMBL22855167 | 0.68 | PLK1 (0.36) | POLBALDH1A1 | |
| SCHEMBL23029946 | 0.67 | HAVCR2 (0.39) | HAVCR2HSD17B10PDE10AKDM4ELMNA | |
| Hydrochloric Acid SCHEMBL31330005 | 0.65 | HAVCR2 (0.35) | HAVCR2HSD17B10PDE10AKDM4EMAPT | |
| SCHEMBL11971106 | 0.65 | CSNK1D (0.43) | POLBALDH1A1 | |
| SCHEMBL17175156 | 0.65 | EGFR (0.45) | HSD17B10KDM4EALDH1A1MAPTTSHR | |
| SCHEMBL23571429 | 0.65 | NPC1 (0.47) | POLBALDH1A1MAPTTSHR | |
| SCHEMBL24857419 | 0.64 | PDE10A (0.34) | HAVCR2HSD17B10PDE10AKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216414-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | UNIV EMORY (US) | 2024-07-04 | — | — | US | disclosed |
| US-20230242533-A9 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242533-A9 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | ATR, CHEK1, CHEK2 | TNKS 150/4885PARP1 218/4885TNKS2 240/4885 |
| US-20240216414-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | SAMHD1, PNP, NUDT1 | TNKS 1975/4885PARP1 2306/4885TNKS2 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.